Skip to main content

New thematic series: Multiscale chromatin dynamics

New Content ItemWe are proud to announce a new cross-journal thematic series between Clinical Epigenetics and Epigenetics Communications, guest edited by Wim Vanden Berghe and Pernette Verschure. The last few years have seen a wealth of knowledge on the role of epigenetic gene regulation in (patho-)physiological processes. New insights relate to the highly dynamic nature of epigenetic systems. Epigenetic regulatory proteins are in constant motion in the nucleus, exchanging between chromatin-bound and unbound states. In addition,  various layers of chromatin folding show defined dynamics. The causal relationship between these dynamics of chromatin and nuclear organization with gene activity and silencing is still an open question of great importance. Find out more about the scope here.

DNA Day 2021 Blog: DNA and its (journal) children

New Content Item (1)Please check out a special DNA Day blog by the University of Bath's Vanessa Tse, recognizing the important breakthroughs we celebrate every April 25th,  and looking at Clinical Epigenetics and its new companion journal Epigenetics Communications.

New thematic series: Epigenetic Biomarkers

New Content ItemWe are proud to announce a new thematic series, guest edited by Dawn DeMeo, James Flanagan, Harold Snieder, and Tomasz K. Wojdacz. We discuss current progress in development of epigenetic biomarkers for clinical use in common complex diseases of aging and welcome both original research and reviews. The sections of the collection include types of epigenetic biomarkers and readiness for IVD use, progress towards clinical use of biomarkers, single versus multiple biomarkers and risk scores, major stages of clinical validation of the biomarker, biomarker detection technologies suitable for IVD use and significance of bioinformatics, and ethics and regulatory aspects of IVD epigenetic biomarkers. Find out more about the scope here.

Featured article: Sperm DNA methylation epimutation biomarker for paternal offspring autism susceptibility

New Content ItemClinical Epigenetics is proud to publish a new research article from the Skinner lab, about a study which was designed to identify a DNA methylation signature in sperm as a potential biomarker to identify paternal offspring autism susceptibility. Observations demonstrate a highly significant set of 805 DMRs in sperm that can potentially act as a biomarker for paternal offspring autism susceptibility. Ancestral or early-life paternal exposures that alter germline epigenetics are anticipated to be a molecular component of ASD etiology. Find more here.

Call for papers: Regenerative Medicine and Epigenetics

New Content Item (1)We are proud to announce our newest thematic series, guest edited by Adele Murrell and Peter Rugg-Gunn. An inevitable outcome upon aging or in certain diseases is the progressive decline in tissue function. A goal of regenerative medicine is to restore normal function through tissue repair or replacement. We examine key concepts in the interplay between regenerative medicine and the multiple layers of epigenetic regulation. Find out more about the scope here.

Featured series: Clinical Epigenetics of COVID-19

New Content ItemIn response to the Coronavirus pandemic, Clinical Epigenetics is welcoming COVID-19 related manuscripts, and will handle these with priority.  Along with our Editors-in-Chief, Section Editor Georges Herbein will handle submissions and helm a solid collection of papers with strong and innovative scientific value.

Announcing the launch of "Epigenetics Communications"!

New Content ItemWe are pleased to announce the launch of a companion journal to Clinical Epigenetics: Epigenetics Communications! Encompassing the broad spectrum of epigenetics research from basic research to innovations towards therapeutic treatments, Epigenetics Communications is an innovative new, open-access journal devoted to the study of epigenetic principles and mechanisms in basic research settings (without requiring a clinical application). This journal will support the publication of manuscripts that contribute to a further understanding of epigenetic mechanisms that impact functioning of systems and organisms. It will also act as a forum to showcase and discuss alternative conclusions/interpretations of well-established epigenetic phenomena based on (re-)analyses of published or new data. As such, we welcome 'systematic studies', be it positive (expected) or negative (non-expected) with respect to its outcome. Find out more here.

Announcing a new Section “Cancer Epigenetics - Hematological Malignancies”

The new section ‘Cancer Epigenetics- Hematological Malignancies’ aims to investigate the role of epigenetic mechanisms in the pathogenesis of hematological malignancies, welcoming submissions based both on translational research and clinical studies. 

Despite the recent progresses in the understanding of the mechanisms of tumorigenesis of malignant hematopoietic cells, acute leukemias remain a disorder displaying poor survival rate; the mechanism(s) for relapse have still not been mechanistically clarified, as uncertain stays the role of the interplay between genome and epigenome deregulations in driving both the primary transformation and the possible relapse.

Studies targeting the role of epigenome deregulation underlying hematopoietic malignancies including the identification and characterization of the epi-landscape as a therapeutic target and/or studies of chromatin modulating drugs and clinical studies targeting epigenetics of hematopoietic malignancies are welcome.

Section Editor:

Jonathan Licht, The University of Florida, USA

Associate Editors:

Joost Martens, Radboud Institute for Molecular Life Sciences, The Netherlands

Saad Z Usmani, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Start submission here.


Clinical Epigenetics of COVID-19
First published: 5 August 2020
Edited by: Georges Herbein

Pollution and Epigenetics
First published: 21 January 2019
Edited by: Steven Gray and Wim Vanden Berghe

Cross-journal collection
Pluripotent Stem Cells
First published: 19 July 2018

Cross-journal collection
Asthma Genetics and Epigenetics
Collection first published: 19 October 2016

Epigenetic Drugs
Edited by: Lucia Altucci & Marianne Rots
First published: 23 May 2016

Breakthroughs in clinical epigenetics
Edited by: Marianne Rots
First published: 1 March 2015

Graphical Abstracts Now Available

Authors submitting to Clinical Epigenetics now have the option to include a Graphical Abstract when they submit their manuscript.  An image may be uploaded during submission which, together with the article title and abstract text, should provide the reader with a visual description of the topic covered in the article. Graphical abstracts will appear in the HTML version of the article (but not in the PDF version). Instructions for including graphical abstracts is available in the Submission Guidelines for the appropriate article types.

From the blog


Lucia AltucciUniversità degli Studi della Campania, Italy
Marianne RotsUniversity Medical Center Groningen, Netherlands  

Aims & Scope

Encompassing the broad spectrum of epigenetics research from basic research to innovations in therapeutic treatments, Clinical Epigenetics is a top tier, open access journal devoted to the study of epigenetic principles and mechanisms as applied to human development, disease, diagnosis and treatment. The journal particularly welcomes submissions involving clinical trials, translational research, new and innovative methodologies and model organisms providing mechanistic insights. The journal is divided into the following sections:

  • Aging and development epigenetics
  • Allergy, immunology, and pathogen epigenetics
  • Cancer epigenetics and diagnostics
  • Cardiovascular epigenetics
  • Endocrinology and metabolic epigenetics
  • Environmental epigenetics
  • Epigenetic biomarkers
  • Epigenetic technologies
  • Epigenetic Drugs, Trials and Therapy
  • Innovative therapies
  • Lifestyle epigenetics
  • Neurology and psychiatry epigenetics
  • Regenerative medicine
  • Reproductive and transgenerational epigenetics

For more information on the section aims and scope visit our section information page. If you are unclear which section would be best suited to your submission, we invite you to submit a pre-submission inquiry by selecting the Contact Us option here.

Editorial Policy Regarding Submissions Focusing on Non-coding RNAs or RNA Modifications

Manuscripts focusing on differential RNA expression levels (coding or non-coding) or on RNA modifications cannot be considered for publication in Clinical Epigenetics since these aspects are not part of epigenetics per se.

In general, non-coding RNAs affect their target genes at the RNA level, which classifies these molecules as post-transcriptional gene expression regulators. The chromatin effects induced by some ncRNA do not yet justify this, to be included as a general mechanism of action of non-coding RNAs. Similarly, although modifications of RNA molecules resemble modifications of DNA or histone proteins, so do post-translational modifications of non-chromatin proteins. As such, RNA modifications are a novel class of markers, but they are not different from general posttranslational protein modifications (which also are not considered part of epigenetics).

For manuscripts on non-coding RNAs or RNA modifications to be considered for publication in Clinical Epigenetics, the authors must provide at least one of the following:

  • data on the molecular epigenetic regulation of the expression of non-coding RNA (or its modifying enzymes); or
  • insights on the mechanism of action of the non-coding RNA on the chromatin and/or functioning of the DNA; or
  • insights in mitotic stability of the RNA-induced effect.

Editorial Policy Regarding Submissions Focusing on In silico research

Manuscripts reporting on straightforward bioinformatic analyses of publicly accessible databases only, cannot be considered for publication in Clinical Epigenetics, unless the manuscript presents:

  • new insights with well-described strong clinical impact and/or
  • additional insights into biological mechanisms (“wet-lab” validations) and/or
  • validations of findings in a replication cohort.

Archival Content

In October 2011, Clinical Epigenetics became a fully open access journal and is now published as part of BioMed Central's portfolio of journals. To view the journal's content prior to this transition, please see SpringerLink.

Annual Journal Metrics